Subscribe to our Email Alerts

Pipeline

Amplia is developing two proprietary, orally available, small molecule FAK inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases:

  • narmafotinib (AMP945): a highly potent and selective inhibitor of FAK
  • AMP886: a highly potent inhibitor of FAK that also inhibits two other validated disease targets (VEGFR3 and FLT3)

ACTRN12620000894998

** NCT05355298

Amplia has successfully completed a Phase 1 clinical trial of narmafotinib in healthy volunteers. On the back of positive data from this trial, Amplia is currently conducting a trial of narmafotinib in patients with pancreatic cancer.

Amplia is continuing to evaluate both narmafotinib and AMP886 in a range of preclinical models of cancer and fibrotic disease to identify future development, partnering, and licensing opportunities.

Pipeline

Amplia is developing two proprietary, orally available, small molecule FAK inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases:​

  • narmafotinib (AMP945): a highly potent and selective inhibitor of FAK​
  • AMP886: a highly potent inhibitor of FAK that also inhibits two other validated disease targets (VEGFR3 and FLT3)​

ACTRN12620000894998

** NCT05355298

Amplia has successfully completed a Phase 1 clinical trial of narmafotinib in healthy volunteers. On the back of positive data from this trial, Amplia is currently conducting a trial of narmafotinib in patients with pancreatic cancer.

Amplia is continuing to evaluate both narmafotinib and AMP886 in a range of preclinical models of cancer and fibrotic disease to identify future development, partnering, and licensing opportunities.